Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
6
×
biotech
6
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
6
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
6
×
texas top stories
wisconsin blog main
wisconsin top stories
cancer
clinical trials
startups
alzheimer's disease
astrazeneca
bristol-myers squibb
fda
merck
pfizer
biogen
cancer immunotherapy
What
bio
roundup
drug
companies
news
week
biotech
debut
fda
moves
nash
acquisitions
alzheimer’s
annual
approval
approved
assessed
attention
august
biggest
biogen’s
biopharmaceutical
black
build
busy
buy
ceo
communities
company’s
conference
continue
convo
daniel
days
decisions
devices
diamond
diamond’s
digital
disease
Language
unset
Current search:
abbvie
×
biotech
×
" eli lilly "
×
" texas blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More